annual general meeting 2017 - fresenius · fresenius medical care: the leader in dialysis for over...

Annual General MeetingFresenius SE & Co. KGaA

May 12, 2017 | Frankfurt/Main

Quirónsalud: Market and quality leader in Spain

Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 2

44 hospitals

~6,600 beds

320,000 inpatients

9.4 million outpatients

As of March 31, 2017

Fresenius Helios: Continued strong commitment to Germany


112 hospitals

~35,000 beds

1.3 million inpatients

3.9 million outpatients

As of March 31, 2017

Fresenius Medical Care: The leader in dialysis for over 20 years


In 2016

~140 million dialyzers

>48,000 dialysis machines

>3,600 dialysis clinics

>300,000 patients

Fresenius Kabi: Strong growth in all areas


In 2016

~80 new I.V. generics

€322 million in investments

~70 production sites

>1 billion infusion solutions

Fresenius Vamed: Continued geographic expansion


Well-balanced revenue distribution in 2016

Services49%

Sales:€1,160 m

Projects51%

Order intake >€1 billion

>800 projects since founding

in ~80 countries

Services for >600 hospitals

In 2016

2015 2016

13th consecutive record year

7

Sales Net incomeEBIT

+5% +9% +12%

According to US-GAAP; in part before special items

2015 2016 2015 2016

€m

Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA

27,62629,083

3,958

4,3271,593

1,423

24th consecutive dividend increase


2

1619

22 23 2529

32

37

4244

55

62

1993 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

2016: Proposed(in euro cents)

CAGR+16%

Fresenius outperforms DAX index

54%

7%


13%

Share price development in 2016

A steadily growing Fresenius workforce

263,957Employees worldwide


104,872

149,351

232,873

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016As ofMarch 31, 2017

An excellent start in 2017

11

+19% +27% +28%

2015 2016

Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA

Q1/16 Q1/17 Q1/16 Q1/17Q1/16 Q1/17

Sales Net incomeEBIT

€m

457

358

1,216

959

8,362

7,015

Group outlook 2017: Double-digit sales and earnings growth


2017:Sales +15-17%Net income +19-21%

Constant currency, according to IFRS, net income before special items

Strategic acquisitions for further growth


• Provider of generic pharmaceuticals

• Plants in the USA, Switzerland and India

• New dosage forms such as eye-drops, creams and sprays

• New treatment areas, for example ophthalmology and dermatology

• “Similar” to its already approved biologic originator drug, a biosimilar is produced using living cells

• Much less expensive than original preparations

• Ideal time to enter biosimilars

• Importance in medicine has been growing steadily

• Many similarities to conventional generics

Ambitious mid-term targets


2020:Sales €43-€47 bnNet income €2.4-€2.7 bn

Fresenius Helios: Learning from the best


Fresenius Medical Care: World’s largest dialysis provider


Fresenius Kabi: Investing in quality


Fresenius Vamed: Projects around the world


Fresenius: Better medicine for more people


Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.


Annual General MeetingFresenius SE & Co. KGaA

May 12, 2017 | Frankfurt/Main

annual general meeting 2017 - fresenius · fresenius medical care: the leader in dialysis for over...

Documents